NCT06627335

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

Pregnancy Outcomes Study of Women With Atopic Dermatitis Exposed to Ruxolitinib Cream Versus Topical Corticosteroids During Pregnancy: A US Claims Database Analysis

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 5,621 (estimated)
• Sponsor: Incyte Corporation · Industry
• Sex: Female
• Age: 14 Years
• Healthy volunteers: Not accepted

Summary

This study is to assess infant outcomes of women with AD who were exposed to ruxolitinib cream during pregnancy compared with a control cohort of women with AD who were exposed to a topical corticosteroid (TCS) during pregnancy.

Conditions

• Pregnancy Related
• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	Ruxolitinib Cream	Ruxolitinib Cream
DRUG	TCS	Topical corticosteroid

Timeline

• Start date: 2023-03-27
• Primary completion: 2027-08-15
• Completion: 2028-08-15
• First posted: 2024-10-04
• Last updated: 2025-12-11

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study